What Prasad's exit means for the FDA moving forward
普拉萨德的离任对FDA未来意味着什么

Vinay Prasad’s second exit from FDA leadership after less than a year in his positions didn’t come as a major surprise. But with his two positions now left to fill — as the director of CBER and as chief medical and scientific officer — there are questions about the agency’s future direction with vaccine and rare disease drug reviews.
维奈•普拉萨德在任职未满一年时第二次离开FDA领导层，并不令人意外。但随着他留下的两个职位——CBER主任和首席医学与科学官——亟待补缺，外界开始质疑该机构在疫苗和罕见病药物审评方面的未来走向。